Ind-Swift Laboratories Converts Warrants Worth Rs 47.06 Crore Into Equity
By Ankur Chandra | Published at: Jul 22, 2025 04:49 PM IST
Chandigarh, July 22, 2025: Ind-Swift Laboratories Limited (BSE: 532305, NSE: INDSWFTLAB) has announced the allotment of 51,85,124 equity shares pursuant to the conversion of fully convertible warrants..
Preferential Allotment Details
At a meeting held on 21 July 2025, the Preferential Issue Committee approved the conversion of warrants into equity shares. These warrants were originally allotted on 30 August 2024 at an issue price of ₹121 per share.
What Is Preferential Allotment?
Preferential allotment is a process by which a company issues shares or convertible securities to a specific group of investors, such as promoters, institutional investors, or strategic partners, at a pre-determined price. Unlike a public issue, it does not involve offering shares to the general public. It’s governed by SEBI regulations and is often used to raise quick capital, bring in strategic investors, or strengthen promoter holding. This route typically requires shareholder and regulatory approval.
Allotment Summary:
| S. No. | Name of Allottee | Category | Shares Allotted (Conversion of Warrants) |
|---|---|---|---|
| 1 | Essix Biosciences Limited | Promoter | 7,00,000 |
| 2 | HCP Investments | Non-Promoter | 44,85,124 |
| Total | 51,85,124 |
This allotment aggregates to a capital infusion of ₹47.06 crore through the conversion of warrants. This process was carried out as per SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, Chapter V, and SEBI Listing Regulations under Regulation 30, read with the Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024.
Capital Structure Update
Post conversion, the company’s paid-up equity share capital stands increased from earlier levels to:
| Particulars | Pre-Allotment | Post-Allotment |
|---|---|---|
| Number of Equity Shares (Face Value ₹10 each) | Not disclosed in this filing | 7,23,86,860 shares |
| Paid-up Share Capital | Not disclosed in this filing | ₹72,38,68,600 |
Regulatory Compliance and Conversion
The conversion reflects full compliance with the terms of the preferential allotment. Both Essix Biosciences and HCP Investments have exercised their rights within the warrant tenure, completing the transaction within the prescribed time frame.
Financial Snapshot
Ind-Swift Laboratories Limited, as of 22 July 2025, trades at around ₹107.25 on the NSE. The company’s market capitalisation stands at approximately ₹714.7 crore. For the fiscal year ended 31 March 2024 (FY24), the company reported a total revenue of ₹1,326.27 crore and a significant profit after tax of ₹420.96 crore. The earnings per share (EPS) for FY24 was ₹71.24. While quarterly results can fluctuate, the company has shown robust long-term financial performance. This recent capital infusion through warrant conversion is expected to strengthen its balance sheet and support future growth initiatives in the API manufacturing and export segments.
What Does This Mean For The Investors?
The warrant conversion and equity allotment by Ind-Swift Labs signals strong promoter and institutional confidence, with a Rs. 47.06 crore capital infusion. The rise in paid-up capital improves the company’s financial flexibility for future expansion. While short-term dilution may affect EPS, the long-term outlook remains positive due to healthy profitability and growth in the API segment. Investors may view this as a signal of strategic growth plans backed by strong fundamentals.
Current Share Price
As of 2:30 PM, the shares of Ind-Swift Laboratories Limited were trading at ₹106.00, down by 0.01% or ₹0.01. It remains to be seen at what price the shares will close at the end of today’s market session.
About the Company
Ind-Swift Laboratories Limited is a publicly listed pharmaceutical company engaged in the manufacturing and export of Active Pharmaceutical Ingredients (APIs). The company is listed on both BSE and NSE and is known for its backwards integration capabilities and focus on regulated markets.
REF:https://nsearchives.nseindia.com/corporate/INDSWFTLAB_22072025140102_Intimation.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
